Article info

Download PDFPDF
Research paper
Dimethyl fumarate: a possible exit strategy from natalizumab treatment in patients with multiple sclerosis at risk for severe adverse events

Authors

  1. Correspondence to Professor Massimiliano Calabrese, Neurology B, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Policlinico “G.B. Rossi” Borgo Roma, Piazzale L A Scuro, Verona 1037134, Italy; massimiliano.calabrese{at}univr.it
View Full Text

Citation

Calabrese M, Pitteri M, Farina G, et al
Dimethyl fumarate: a possible exit strategy from natalizumab treatment in patients with multiple sclerosis at risk for severe adverse events

Publication history

  • Received April 11, 2017
  • Revised July 8, 2017
  • Accepted August 6, 2017
  • First published August 26, 2017.
Online issue publication 
December 12, 2017

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.